Study of TEV-50717 for the Treatment of Tourette Syndrome in Children and Adolescents

Study Title
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Teva Identifier
TV50717-CNS-30046 | 2016-000622-19
ClinicalTrials.gov Identifier
NCT03452943
Study Status
Completed
Trial Condition(s)
Tourette Syndrome
Interventions
Drug: TEV-50717 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
6 Years to 16 Years
Trial Duration
February 5, 2018 - November 12, 2019
Phase
Phase 2/3

Additional info

Study Type

Interventional